Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 427

1.

Lack of Efficacy of High-Titered Immunoglobulin in Patients with West Nile Virus Central Nervous System Disease.

Gnann JW Jr, Agrawal A, Hart J, Buitrago M, Carson P, Hanfelt-Goade D, Tyler K, Spotkov J, Freifeld A, Moore T, Reyno J, Masur H, Jester P, Dale I, Li Y, Aban I, Lakeman FD, Whitley RJ; National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group .

Emerg Infect Dis. 2019 Nov;25(11):2064-2073. doi: 10.3201/eid2511.190537.

2.

Metabolic Changes in Chronic Hepatitis C Patients who Carry IFNL4-ΔG and Achieve Sustained Virologic Response with Direct-Acting Antiviral Therapy.

Emmanuel B, El-Kamary SS, Magder LS, Stafford KA, Charurat ME, Chairez C, McLaughlin M, Hadigan C, Prokunina-Olsson L, O'Brien TR, Masur H, Kottilil S.

J Infect Dis. 2019 Aug 26. pii: jiz435. doi: 10.1093/infdis/jiz435. [Epub ahead of print]

PMID:
31504644
3.

A pilot study of safety and efficacy of HCV retreatment with sofosbuvir/velpatasvir/voxilaprevir in patients with or without HIV (RESOLVE STUDY).

Wilson E, Covert E, Hoffmann J, Comstock E, Emmanuel B, Tang L, Husson J, Chua J, Price A, Mathur P, Rosenthal E, Kattakuzhy S, Masur H, Kottilil S.

J Hepatol. 2019 Sep;71(3):498-504. doi: 10.1016/j.jhep.2019.05.021. Epub 2019 Jun 5.

PMID:
31173815
4.

Immunological recovery in T-cell activation after sustained virologic response among HIV positive and HIV negative chronic Hepatitis C patients.

Emmanuel B, El-Kamary SS, Magder LS, Stafford KA, Charurat ME, Poonia B, Chairez C, McLaughlin M, Hadigan C, Masur H, Kottilil S.

Hepatol Int. 2019 May;13(3):270-276. doi: 10.1007/s12072-019-09941-8. Epub 2019 Mar 5.

PMID:
30835046
5.

Workforce, Workload, and Burnout Among Intensivists and Advanced Practice Providers: A Narrative Review.

Pastores SM, Kvetan V, Coopersmith CM, Farmer JC, Sessler C, Christman JW, D'Agostino R, Diaz-Gomez J, Gregg SR, Khan RA, Kapu AN, Masur H, Mehta G, Moore J, Oropello JM, Price K; Academic Leaders in Critical Care Medicine (ALCCM) Task Force of the Society of the Critical Care Medicine.

Crit Care Med. 2019 Apr;47(4):550-557. doi: 10.1097/CCM.0000000000003637.

PMID:
30688716
6.

Multitarget Direct-Acting Antiviral Therapy Is Associated With Superior Immunologic Recovery in Patients Coinfected With Human Immunodeficiency Virus and Hepatitis C Virus.

Shrivastava S, Bhatta M, Ward H, Romani S, Lee R, Rosenthal E, Osinusi A, Kohli A, Masur H, Kottilil S, Wilson E.

Hepatol Commun. 2018 Sep 27;2(12):1451-1466. doi: 10.1002/hep4.1258. eCollection 2018 Dec.

8.

Characterization of changes in intrahepatic immune cell populations during HCV treatment with sofosbuvir and ribavirin.

Orr C, Aartun J, Masur H, Kottilil S, Meissner EG.

J Viral Hepat. 2019 Mar;26(3):323-328. doi: 10.1111/jvh.13034. Epub 2018 Dec 3.

PMID:
30383918
9.

HBV induces inhibitory FcRL receptor on B cells and dysregulates B cell-T follicular helper cell axis.

Poonia B, Ayithan N, Nandi M, Masur H, Kottilil S.

Sci Rep. 2018 Oct 17;8(1):15296. doi: 10.1038/s41598-018-33719-x.

10.

Reply to Al-Hasan and Justo.

Kalil AC, Gilbert DN, Winslow DL, Masur H, Klompas M; IDSA Sepsis Task Force.

Clin Infect Dis. 2019 Apr 8;68(8):1432. doi: 10.1093/cid/ciy679. No abstract available.

11.

Expansion of Treatment for Hepatitis C Virus Infection.

Emmanuel B, Masur H, Kottilil S, Kattakuzhy S.

Ann Intern Med. 2018 Mar 20;168(6):457-459. doi: 10.7326/L17-0698. No abstract available.

PMID:
29554678
12.

Management of Antiretrovirals in Critically Ill Patients: Great Progress But Potential Pitfalls.

Suffredini DA, George JM, Masur H.

Crit Care Med. 2018 May;46(5):663-665. doi: 10.1097/CCM.0000000000003048. No abstract available.

13.

Critical Care Organizations: Building and Integrating Academic Programs.

Moore JE, Oropello JM, Stoltzfus D, Masur H, Coopersmith CM, Nates J, Doig C, Christman J, Hite RD, Angus DC, Pastores SM, Kvetan V; Academic Leaders in Critical Care Medicine (ALCCM) Task Force of the Society of the Critical Care Medicine.

Crit Care Med. 2018 Apr;46(4):e334-e341. doi: 10.1097/CCM.0000000000002917.

14.

Does HIV Really Augment the Frequency or Mortality Risk of Increased Pulmonary Artery Systolic Pressures?

Sachdev V, Solomon MA, Masur H.

Am J Respir Crit Care Med. 2018 Apr 1;197(7):854-855. doi: 10.1164/rccm.201711-2271ED. No abstract available.

15.

Rapid changes in peripheral lymphocyte concentrations during interferon-free treatment of chronic hepatitis C virus infection.

Meissner EG, Kohli A, Higgins J, Lee YJ, Prokunina O, Wu D, Orr C, Masur H, Kottilil S.

Hepatol Commun. 2017 Sep;1(7):586-594. doi: 10.1002/hep4.1074. Epub 2017 Jul 24.

16.

No Improvement in Hemoglobin A1c Following Hepatitis C Viral Clearance in Patients With and Without HIV.

Chaudhury CS, Sheehan J, Chairez C, Akoth E, Gross C, Silk R, Kattakuzhy S, Rosenthal E, Kottilil S, Masur H, Hadigan C.

J Infect Dis. 2017 Dec 27;217(1):47-50. doi: 10.1093/infdis/jix517.

17.

Expansion of Treatment for Hepatitis C Virus Infection by Task Shifting to Community-Based Nonspecialist Providers: A Nonrandomized Clinical Trial.

Kattakuzhy S, Gross C, Emmanuel B, Teferi G, Jenkins V, Silk R, Akoth E, Thomas A, Ahmed C, Espinosa M, Price A, Rosenthal E, Tang L, Wilson E, Bentzen S, Masur H, Kottilil S; and the ASCEND Providers.

Ann Intern Med. 2017 Sep 5;167(5):311-318. doi: 10.7326/M17-0118. Epub 2017 Aug 8.

18.

Disparities in achieving and sustaining viral suppression among a large cohort of HIV-infected persons in care - Washington, DC.

Castel AD, Kalmin MM, Hart RL, Young HA, Hays H, Benator D, Kumar P, Elion R, Parenti D, Ruiz ME, Wood A, D'Angelo L, Rakhmanina N, Rana S, Bryant M, Hebou A, Fernández R, Abbott S, Peterson J, Wood K, Subramanian T, Binkley J, Happ LP, Kharfen M, Masur H, Greenberg AE.

AIDS Care. 2016 Nov;28(11):1355-64. doi: 10.1080/09540121.2016.1189496. Epub 2016 Jun 13.

19.

Simtuzumab treatment of advanced liver fibrosis in HIV and HCV-infected adults: results of a 6-month open-label safety trial.

Meissner EG, McLaughlin M, Matthews L, Gharib AM, Wood BJ, Levy E, Sinkus R, Virtaneva K, Sturdevant D, Martens C, Porcella SF, Goodman ZD, Kanwar B, Myers RP, Subramanian M, Hadigan C, Masur H, Kleiner DE, Heller T, Kottilil S, Kovacs JA, Morse CG.

Liver Int. 2016 Dec;36(12):1783-1792. doi: 10.1111/liv.13177. Epub 2016 Jul 6.

20.

The pharmacist: An indispensable partner in HIV care.

Pau AK, Lane HC, Masur H.

Am J Health Syst Pharm. 2016 Apr 1;73(7):431. doi: 10.2146/ajhp160077. No abstract available.

PMID:
27001981
21.

Pneumocystis jirovecii Pneumonia in Human Immunodeficiency Virus Infection.

Siegel M, Masur H, Kovacs J.

Semin Respir Crit Care Med. 2016 Apr;37(2):243-56. doi: 10.1055/s-0036-1579556. Epub 2016 Mar 14. Review.

PMID:
26974301
22.

Critical Care Medicine After the 2014-2015 Ebola Outbreak: Are We Ready If It Happens Again?

Chertow DS, Palmore TN, Masur H.

Crit Care Med. 2016 Mar;44(3):457-9. doi: 10.1097/CCM.0000000000001590. No abstract available.

PMID:
26901541
23.

Achieving sustained virologic response after interferon-free hepatitis C virus treatment correlates with hepatic interferon gene expression changes independent of cirrhosis.

Meissner EG, Kohli A, Virtaneva K, Sturdevant D, Martens C, Porcella SF, McHutchison JG, Masur H, Kottilil S.

J Viral Hepat. 2016 Jul;23(7):496-505. doi: 10.1111/jvh.12510. Epub 2016 Feb 3.

24.

Effect of HIV co-infection on adherence to a 12-week regimen of hepatitis C virus therapy with ledipasvir and sofosbuvir.

Townsend K, Petersen T, Gordon LA, Kohli A, Nelson A, Seamon C, Gross C, Tang L, Osinusi A, Polis MA, Masur H, Kottilil S.

AIDS. 2016 Jan;30(2):261-6. doi: 10.1097/QAD.0000000000000903.

PMID:
26691547
25.

High adherence to all-oral directly acting antiviral HCV therapy among an inner-city patient population in a phase 2a study.

Petersen T, Townsend K, Gordon LA, Sidharthan S, Silk R, Nelson A, Gross C, Calderón M, Proschan M, Osinusi A, Polis MA, Masur H, Kottilil S, Kohli A.

Hepatol Int. 2016 Mar;10(2):310-9. doi: 10.1007/s12072-015-9680-7. Epub 2015 Nov 26.

26.

Four-Week Direct-Acting Antiviral Regimens in Noncirrhotic Patients With Hepatitis C Virus Genotype 1 Infection: An Open-Label, Nonrandomized Trial.

Kohli A, Kattakuzhy S, Sidharthan S, Nelson A, McLaughlin M, Seamon C, Wilson E, Meissner EG, Sims Z, Silk R, Gross C, Akoth E, Tang L, Price A, Jolley TA, Emmanuel B, Proschan M, Teferi G, Chavez J, Abbott S, Osinusi A, Mo H, Polis MA, Masur H, Kottilil S.

Ann Intern Med. 2015 Dec 15;163(12):899-907. doi: 10.7326/M15-0642. Epub 2015 Nov 24.

PMID:
26595450
27.

Interferon-Free Treatment of Hepatitis C Virus in HIV/Hepatitis C Virus-Coinfected Subjects Results in Increased Serum Low-Density Lipoprotein Concentration.

Townsend K, Meissner EG, Sidharthan S, Sampson M, Remaley AT, Tang L, Kohli A, Osinusi A, Masur H, Kottilil S.

AIDS Res Hum Retroviruses. 2016 May;32(5):456-62. doi: 10.1089/AID.2015.0170. Epub 2015 Dec 15.

28.

Successful Retreatment of Chronic HCV Genotype-1 Infection With Ledipasvir and Sofosbuvir After Initial Short Course Therapy With Direct-Acting Antiviral Regimens.

Wilson EM, Kattakuzhy S, Sidharthan S, Sims Z, Tang L, McLaughlin M, Price A, Nelson A, Silk R, Gross C, Akoth E, Mo H, Subramanian GM, Pang PS, McHutchison JG, Osinusi A, Masur H, Kohli A, Kottilil S.

Clin Infect Dis. 2016 Feb 1;62(3):280-288. doi: 10.1093/cid/civ874. Epub 2015 Oct 31.

29.

HIV-Related Opportunistic Infections Are Still Relevant in 2015.

Masur H.

Top Antivir Med. 2015 Aug-Sep;23(3):116-9.

30.

Moderate Sustained Virologic Response Rates With 6-Week Combination Directly Acting Anti-Hepatitis C Virus Therapy in Patients With Advanced Liver Disease.

Kattakuzhy S, Wilson E, Sidharthan S, Sims Z, McLaughlin M, Price A, Silk R, Gross C, Akoth E, McManus M, Emmanuel B, Shrivastava S, Tang L, Nelson A, Teferi G, Chavez J, Lam B, Mo H, Osinusi A, Polis MA, Masur H, Kohli A, Kottilil S.

Clin Infect Dis. 2016 Feb 15;62(4):440-447. doi: 10.1093/cid/civ897. Epub 2015 Oct 26.

31.

Hepatitis C Virus Infection among Hematopoietic Cell Transplant Donors and Recipients: American Society for Blood and Marrow Transplantation Task Force Recommendations.

Torres HA, Chong PP, De Lima M, Friedman MS, Giralt S, Hammond SP, Kiel PJ, Masur H, McDonald GB, Wingard JR, Gambarin-Gelwan M.

Biol Blood Marrow Transplant. 2015 Nov;21(11):1870-82. doi: 10.1016/j.bbmt.2015.07.033. Epub 2015 Aug 6. Review. No abstract available.

32.

Ledipasvir and sofosbuvir for hepatitis C genotype 4: a proof-of-concept, single-centre, open-label phase 2a cohort study.

Kohli A, Kapoor R, Sims Z, Nelson A, Sidharthan S, Lam B, Silk R, Kotb C, Gross C, Teferi G, Sugarman K, Pang PS, Osinusi A, Polis MA, Rustgi V, Masur H, Kottilil S.

Lancet Infect Dis. 2015 Sep;15(9):1049-1054. doi: 10.1016/S1473-3099(15)00157-7. Epub 2015 Jul 14.

33.

Dynamic Changes of Post-Translationally Modified Forms of CXCL10 and Soluble DPP4 in HCV Subjects Receiving Interferon-Free Therapy.

Meissner EG, Decalf J, Casrouge A, Masur H, Kottilil S, Albert ML, Duffy D.

PLoS One. 2015 Jul 16;10(7):e0133236. doi: 10.1371/journal.pone.0133236. eCollection 2015. Erratum in: PLoS One. 2015;10(9):e0139818.

34.

Opportunistic Infections and Mortality: Still Room for Improvement.

Masur H, Read SW.

J Infect Dis. 2015 Nov 1;212(9):1348-50. doi: 10.1093/infdis/jiv236. Epub 2015 Jun 3. No abstract available.

35.

Bad bugs, no drugs: are we part of the problem, or leaders in developing solutions?

Decker B, Masur H.

Crit Care Med. 2015 Jun;43(6):1153-5. doi: 10.1097/CCM.0000000000001039. No abstract available.

PMID:
25978153
36.

Treatment of hepatitis C virus infection.

Kottilil S, Wright M, Polis MA, Masur H.

Ann Intern Med. 2015 Mar 17;162(6):459. doi: 10.7326/L15-5064-4. No abstract available.

PMID:
25775329
37.

Utility of hepatitis C viral load monitoring on direct-acting antiviral therapy.

Sidharthan S, Kohli A, Sims Z, Nelson A, Osinusi A, Masur H, Kottilil S.

Clin Infect Dis. 2015 Jun 15;60(12):1743-51. doi: 10.1093/cid/civ170. Epub 2015 Mar 2.

38.

Virologic response following combined ledipasvir and sofosbuvir administration in patients with HCV genotype 1 and HIV co-infection.

Osinusi A, Townsend K, Kohli A, Nelson A, Seamon C, Meissner EG, Bon D, Silk R, Gross C, Price A, Sajadi M, Sidharthan S, Sims Z, Herrmann E, Hogan J, Teferi G, Talwani R, Proschan M, Jenkins V, Kleiner DE, Wood BJ, Subramanian GM, Pang PS, McHutchison JG, Polis MA, Fauci AS, Masur H, Kottilil S.

JAMA. 2015 Mar 24-31;313(12):1232-9. doi: 10.1001/jama.2015.1373.

PMID:
25706232
39.

Virological response after 6 week triple-drug regimens for hepatitis C: a proof-of-concept phase 2A cohort study.

Kohli A, Osinusi A, Sims Z, Nelson A, Meissner EG, Barrett LL, Bon D, Marti MM, Silk R, Kotb C, Gross C, Jolley TA, Sidharthan S, Petersen T, Townsend K, Egerson D, Kapoor R, Spurlin E, Sneller M, Proschan M, Herrmann E, Kwan R, Teferi G, Talwani R, Diaz G, Kleiner DE, Wood BJ, Chavez J, Abbott S, Symonds WT, Subramanian GM, Pang PS, McHutchison J, Polis MA, Fauci AS, Masur H, Kottilil S.

Lancet. 2015 Mar 21;385(9973):1107-13. doi: 10.1016/S0140-6736(14)61228-9. Epub 2015 Jan 13.

40.

HIV/AIDS.

Saag MS, Masur H.

Infect Dis Clin North Am. 2014 Dec;28(4):ix-x. doi: 10.1016/j.idc.2014.09.001. Epub 2014 Nov 20. No abstract available.

PMID:
25455316
41.

Sustained Virologic Response for Chronic Hepatitis C Infection after 27 Days of Treatment with Sofosbuvir and Ribavirin.

Meissner EG, Nelson A, Marti M, Masur H, Osinusi A, Kottilil S.

Open Forum Infect Dis. 2014 Spring;1(1):013.

42.

The authors reply.

Opal SM, Dellinger RP, Vincent JL, Masur H, Angus DC.

Crit Care Med. 2014 Dec;42(12):e798-9. doi: 10.1097/CCM.0000000000000681. No abstract available.

PMID:
25402303
43.

Re-treatment of chronic hepatitis C virus genotype 1 infection after relapse: an open-label pilot study.

Osinusi A, Kohli A, Marti MM, Nelson A, Zhang X, Meissner EG, Silk R, Townsend K, Pang PS, Subramanian GM, McHutchison JG, Fauci AS, Masur H, Kottilil S.

Ann Intern Med. 2014 Nov 4;161(9):634-8. doi: 10.7326/M14-1211.

44.

Treatment of hepatitis C virus infection: is it time for the internist to take the reins?

Kottilil S, Wright M, Polis MA, Masur H.

Ann Intern Med. 2014 Sep 16;161(6):443-4. doi: 10.7326/M14-0741. No abstract available.

PMID:
25222390
45.

Effect of sofosbuvir and ribavirin treatment on peripheral and hepatic lipid metabolism in chronic hepatitis C virus, genotype 1-infected patients.

Meissner EG, Lee YJ, Osinusi A, Sims Z, Qin J, Sturdevant D, McHutchison J, Subramanian M, Sampson M, Naggie S, Patel K, Remaley AT, Masur H, Kottilil S.

Hepatology. 2015 Mar;61(3):790-801. doi: 10.1002/hep.27424. Epub 2015 Jan 28.

46.

Hepatic compartmentalization of exhausted and regulatory cells in HIV/HCV-coinfected patients.

Barrett L, Trehanpati N, Poonia S, Daigh L, Sarin SK, Masur H, Kottilil S.

J Viral Hepat. 2015 Mar;22(3):281-8. doi: 10.1111/jvh.12291. Epub 2014 Sep 1.

PMID:
25174689
47.

HIV/AIDS.

Saag MS, Masur H.

Infect Dis Clin North Am. 2014 Sep;28(3):xv-xvi. doi: 10.1016/j.idc.2014.07.001. No abstract available.

PMID:
25151570
48.

Infections in the immunosuppressed host.

George MP, Masur H, Norris KA, Palmer SM, Clancy CJ, McDyer JF.

Ann Am Thorac Soc. 2014 Aug;11 Suppl 4:S211-20. doi: 10.1513/AnnalsATS.201401-038PL. Review.

49.

Endogenous intrahepatic IFNs and association with IFN-free HCV treatment outcome.

Meissner EG, Wu D, Osinusi A, Bon D, Virtaneva K, Sturdevant D, Porcella S, Wang H, Herrmann E, McHutchison J, Suffredini AF, Polis M, Hewitt S, Prokunina-Olsson L, Masur H, Fauci AS, Kottilil S.

J Clin Invest. 2014 Aug;124(8):3352-63. doi: 10.1172/JCI75938. Epub 2014 Jul 1.

50.

Short communication: serum-based assay accurately detects single nucleotide polymorphisms of IL28B and SOCS3 in HIV/hepatitis C virus-coinfected subjects.

Shaffer A, Hubbard JJ, Townsend K, Kottilil S, Polis MA, Masur H, Kohli A.

AIDS Res Hum Retroviruses. 2014 Aug;30(8):792-5. doi: 10.1089/AID.2014.0028. Epub 2014 Jul 14.

Supplemental Content

Support Center